marketed medication used treating spinal muscular atrophy sma rare neuromuscular december became first approved drug used treating disorder since condition treats rare nusinersen socalled orphan drug designation united states european drug used treat spinal muscular atrophy associated mutation gene administered directly central nervous system cns using intrathecal clinical trials drug halted disease progression around infants affected type spinal muscular atrophy improves motor people treated nusinersen increased risk upper lower respiratory infections congestion ear infections constipation pulmonary aspiration teething scoliosis risk growth infants children might stunted older clinical trial subjects common adverse events headache back pain adverse effects spinal injection postduralpuncture although observed trial patients reduction platelets well risk kidney damage theoretical risks antisense drugs therefore platelets kidney function monitored several cases communicating hydrocephalus children adults treated nusinersen emerged remains unclear whether drug spinal muscular atrophy caused lossoffunction mutations gene codes survival motor neuron smn protein people survive owing low amounts smn protein produced gene nusinersen modulates alternative splicing gene functionally converting gene thus increasing level smn protein drug distributes cns peripheral halflife estimated days cerebrospinal fluid csf days blood plasma drug metabolized via exonuclease hydrolysis interact primary route elimination likely urinary excretion nusinersen nusinersen antisense oligonucleotide groups ribofuranosyl rings replaced groups phosphate linkages replaced phosphorothioate nusinersen developed collaboration adrian krainer cold spring harbor laboratory ionis pharmaceuticals formerly called isis initial work target discovery nusinersen done dr ravindra singh coworkers university massachusetts medical school funded cure starting ionis partnered biogen development biogen acquired exclusive license drug million license fee milestone payments million tiered royalties thereafter biogen also paid costs development subsequent taking license biogen included licenses intellectual property ionis acquired cold spring harbor laboratory university november new drug application accepted fdas priority review process strength phase iii trial unmet need also accepted review european medicines agency ema approved fda december ema may first drug treat subsequently nusinersen approved treat sma canada july japan july brasil august switzerland september china february nusinersen list price usa per injection puts treatment cost first year annually according new york times places nusinersen among expensive drugs october authorities denmark recommended nusinersen use small subset people sma type young babies refused offer standard treatment people sma quoting unreasonably high price compared norwegian authorities rejected funding october price medicine unethically february funding approved people years april funding expanded include august national institute health care excellence nice weighs costeffectiveness therapies nhs england wales recommended offering nusinersen people children sma type treated uk biogenfunded expanded access programme enrolling children scheme closed new people november may however nice reversed stance announced decision recommend nusinersen use across wide spectrum sma irish health service executive decided february nusinersen expensive fund saying cost would per patient first year around year thereafter estimated budget impact excess million fiveyear period children sma living ireland manufacturer patient groups disputed numbers pointed actual pricing arrangements ireland line negotiated price beneluxa initiative ireland member since june may nusinersen available public healthcare december nusinersen included extended insurance coverage china price reduced per vial around per httpsenwikipediaorgwikinusinersen